Summary
Recent results from the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure [EMPHASIS-HF] trial showed that eplerenone, compared with placebo, significantly reduced the risk of the composite of cardiovascular death and hospitalization for heart failure in patients with chronic systolic NYHA class II HF [NCT00232180; Zannad F et al. N Engl J Med 2011].
- Cardiology Clinical Trials
- Heart Failure
- © 2011 MD Conference Express
Tools
Table of contents
Cited By...
- No citing articles found.